Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials

BMC Medical Research Methodology

Volumn 11, Issue , 2011, Pages

  Mieno, Makiko N ^a   Yamaguchi, Takuhiro ^b   Ohashi, Yasuo ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 80955176416     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-11-80     Document Type: Article

References (24)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group, Neurology 1993 43 655 661 8469318
2. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. T Saida K Tashiro Y Itoyama T Sato Y Ohashi Z Zhao, Neurology 2005 64 621 630 15728282 (Pubitemid 40261889)
3. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. L Kappos CH Polman MS Freedman G Edan HP Hartung DH Miller X Montalban L Bauer P Jakobs C Pohl R Sandbrink, Neurology 2006 67 1242 1249 10.1212/01.wnl. 0000237641.33768.8d 16914693 (Pubitemid 44563835)
4. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit. WM Carroll, Mult Scler 2009 15 951 958 10.1177/1352458509105426 19465446
5. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. The PRISMS Study Group, Lancet 1998 352 1498 1504 10.1016/S0140-6736(98)03334-0 9820297
6. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. KP Johnson BR Brooks JA Cohen CC Ford J Goldstein RP Lisak LW Myers HS Panitch JW Rose RB Schiffer, Neurology 1995 45 1268 1276 7617181
7. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. F Fazekas F Deisenhammer S Strasser-Fuchs G Nahler B Mamoli, Lancet 1997 349 589 593 10.1016/S0140-6736(96) 09377-4 9057729 (Pubitemid 27101884)
8. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. PS Sorensen B Wanscher CV Jensen K Schreiber M Blinkenberg M Ravnborg H Kirsmeier VA Larsen ML Lee, Neurology 1998 50 1273 1281 9595974 (Pubitemid 28240339)
9. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Neurology 1999 53 457 465 10449104
10. A controlled trial of natalizumab for relapsing multiple sclerosis. DH Miller OA Kahn WA Sheremata LD Blumhardt GP Rive MA Libonati AJ Willmer-Hulme CM Dalton KA Miszkiel PW O'Connor, N Engl J Med 2003 348 15 23 10.1056/NEJMoa020696 12510038 (Pubitemid 36026342)
11. TM Therneau PM Grambsch, Modeling Survival Data: Extending the Cox Model New York: Springer-Verlag 2000
12. Statistical methods for the analysis of relapse data in MS clinical trials. YC Wang L Meyerson YQ Tang N Qian, J Neurol Sci 2009 285 206 211 10.1016/j.jns.2009.07.017 19709676
13. Recurrent event data analysis: A review. T Yamaguchi, Japanese Journal of Biometrics 2005 26 81 117
14. RJ Cook JF Lawless, The Statistical Analysis of Recurrent Events New York: Springer 2007
15. On reporting results from randomized controlled trials with recurrent events. L Kuramoto BG Sobolev MG Donaldson, BMC Medical Research Methodology 2008 8 35 10.1186/1471-2288-8-35 18513418
16. JP Klein ML Moeschberger, Survival Analysis: Techniques for Censored and Truncated Data New York: Springer 2 2003
17. Cox's regression model for counting processes: a large sample study. PK Andersen RD Gill, Ann Stat 1982 10 1100 1120 10.1214/aos/1176345976
18. On the regression analysis of multivariate failure time data. RL Prentice BJ Williams AV Peterson, Biometrika 1981 68 373 379 10.1093/biomet/68.2.373
19. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. LJ Wei DY Lin L Weissfeld, J Am Stat Assoc 1989 84 1065 1073 10.2307/2290084
20. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. EW Lee LJ Wei DA Amato, Survival Analysis: State of the Art 1992 237 247
21. Longitudinal data analysis using generalized linear models. KY Liang SL Zeger, Biometrika 1986 73 13 22 10.1093/biomet/73.1.13
22. The importance of varying the event generation process in simulation studies of statistical methods for recurrent events. C Metcalfe SG Thompson, Stat Med 2006 25 165 179 10.1002/sim.2310 16217859 (Pubitemid 43136955)
23. Treatment of multiple sclerosis with mizoribine: (1) clinical results of a double-blind, placebo-controlled study. T Saida Y Ohashi K Tashiro Y Itoyama T Sato K Hamaguchi H Nishitani H Shibasaki S Araki Research committee for treatment of multiple sclerosis (Chairman: Igata A), Neuroimmunology 1998 6 160 161
24. The natural history of multiple sclerosis: implications for trial design. DM Wingerchuk BG Weinshenker, Curr Opin Neurol 1999 12 345 349 10.1097/00019052-199906000-00013 10499179 (Pubitemid 29378168)